Table 1.
Baseline Characteristics of the Study Patients*
| Overall (n=80) | Infrequent follow-ups after ESRF (n = 58) | Frequent follow-ups after ESRF (n = 22) | p-value** | |
|---|---|---|---|---|
| Age at SLE onset, years | 27 (19, 37) | 28 (20, 38) | 26 (7, 33) | 0.30 |
| n (%) female | 70 (88) | 49 (84) | 21 (95) | 0.19 |
| Race, n (%) Black† | 45 (63) | 32 (65) | 13 (59) | 0.62 |
| Ethnicity, n (%) Hispanic† | 36 (51) | 27 (52) | 9 (47) | 0.73 |
| One or more visits pre-ESRF per year, n (%) | 23 (29) | 12 (21%) | 11 (50) | 0.01 |
| Yrs from SLE onset to ESRF | 5 (1, 10) | 6 (2, 10) | 2 (1, 7) | 0.21 |
| Yrs from ESRF to last follow-up | 5 (3, 9) | 6 (3, 11) | 4 (2, 9) | 0.38 |
| Yrs between ESRF and death | 3 (2, 7) | 3 (1, 6) | 5 (2, 12) | 0.42 |
| Renal Transplants, n (%) | 34 (43) | 26 (45) | 8 (36) | 0.49 |
| No medications, n (%) | 14 (18) | 13 (22) | 1 (5) | 0.02 |
| Prednisone alone, n (%) | 15 (19) | 11 (19) | 4 (18) | 0.43 |
| Immunosuppresives, n (%) | 36 (45) | 27 (47) | 9 (41) | 0.65 |
| Hydroxychloroquine, n (%) | 25 (31) | 13 (22) | 12 (55) | 0.006 |
| Pred/HCQ combination, n (%) | 15 (19 ) | 7 (12) | 8 (36) | <0.001 |
*
Continuous variables are reported as median (IQR)
**
P values in bold typeface indicate statistical significance.
†
9 missing race/ethnicity data